1) human primary breast invasive ductal carcinoma
原发性乳腺浸润性导管癌
1.
Objective To determinate whether human primary breast invasive ductal carcinoma(HPBIDC) expresses somatostatin receptor(SSTR).
方法应用免疫组化法(IHC)检测82例原发性乳腺浸润性导管癌组织中SSTR的表达,分析其与临床病理因素的关系。
2) breast invasive ductal carcinoma
乳腺浸润性导管癌
1.
The different study of the expression of TSP,MVD and erbB4 gene in breast invasive ductal carcinoma between Han and Uygur;
维吾尔族和汉族乳腺浸润性导管癌TSP、MVD、erbB4表达的差异
2.
Expression of Ets-1 and VEGF in breast invasive ductal carcinoma and its clinical significance
Ets-1、VEGF在乳腺浸润性导管癌组织的表达及其临床意义
3.
Objective: To investigate the expression of pituitary tumor transfor-ming gene (PTTG), matrix metalloproteinase-14 (MMP-14) and vascular endothelial growth factor-C (VEGF-C) in human breast invasive ductal carcinoma.
目的:检测乳腺浸润性导管癌与乳腺良性病变组织中垂体瘤转化基因(PTTG),基质金属蛋白酶-14(MMP-14)和血管内皮生长因子-C(VEGF-C)的表达,探讨它们与乳腺浸润性导管癌淋巴结转移的关系及其临床病理意义。
3) breast infiltrating ductal carcinoma
乳腺浸润性导管癌
1.
Expression of C-erbB-2 in human breast infiltrating ductal carcinoma and its implication;
C-erbB-2在乳腺浸润性导管癌中的表达及意义
2.
Objective: To investigate the expressions of presenilin-2 (PS2) and glutathione S transferase π (GSTπ) and their roles in prognosis and therapy of breast infiltrating ductal carcinoma.
目的了解乳腺浸润性导管癌中雌激素调节蛋白(PS2)和谷胱甘肽S-转移酶π(GSTπ)的表达及其对预后和治疗的指导作用。
3.
Methods Formalin-fixed, paraffin-embedded tissues of 30 cases of breast usual ductal hyperplasia (UDH), 30 cases of breast atypical ductal hyperplasia (ADH) and 36 cases of breast infiltrating ductal carcinoma (IDC) were detected by immunohistochemistry assay using monoclonal antibodies of TSG101, MDM2 and ER.
方法 采用免疫组织化学方法检测30例乳腺普通型导管增生(UDH)、30例乳腺不典型导管增生(ADH)以及36例乳腺浸润性导管癌(IDC)石蜡包埋组织中TSG101、MDM2及ER蛋白的表达水平,应用SPSS10。
4) invasive ductal carcinoma
乳腺浸润性导管癌
1.
Expression and significance of Maspin and p53 in invasive ductal carcinoma;
Maspin、p53在乳腺浸润性导管癌中的表达及其意义
2.
Objective:To study the expression of PPARγ and PTEN in intraductal proliferative lesions,invasive ductal carcinoma and analyze the influence of breast cancer.
(3)PPARγ和PTEN在乳腺浸润性导管癌中的阳性表达呈负相关(r=-0。
5) invasive ductual breast carcinoma
浸润性乳腺导管癌
6) invasive ductal carcinoma of breast
乳腺浸润性导管癌
1.
Objective: To investigate the expression and their correlation of BCRP、HIF-1a and HER-2 in invasive ductal carcinoma of breast,to elucidate their relationships with clinicopathologic Parameters,ER/PR status,and Disease Free Survival Time in human breast cancer.
目的:通过检测乳腺浸润性导管癌组织中BCRP、HIF-1a、HER-2的表达,探讨其相关性,分析三者与乳腺癌临床病理特征、雌、孕激素受体表达情况的关系及对患者无瘤生存期的影响,为优化乳腺癌的化学治疗、预测疗效提供参考依据。
2.
Objectives To investigate the expressions of BCRP,HIF-1α and HER-2 and their correlation in invasive ductal carcinoma of breast,so as to elucidate their relationship with breast cancer clinicoPathologic Parameters.
目的探讨乳腺浸润性导管癌组织中乳腺癌耐药蛋白(BCRP)、缺氧诱导因子-1α(HIF-1α)、人类表皮生长因子受体-2(HER-2)的表达及临床意义。
补充资料:膀胱浸润性癌
膀胱浸润性癌
infiltrating carcinoma of bladder
又称“实体性癌”。恶性度高,无乳头,表面不平,有显著坏死及钙盐沉着,溃疡边缘呈结节状,早期向深处浸润,转移较早。
说明:补充资料仅用于学习参考,请勿用于其它任何用途。
参考词条